This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duguay, D. Articles by Hiscott, J. Search for Related Content PubMed PubMed Citation Articles by Duguay, D. Articles by Hiscott, J.

In Vivo Interferon Regulatory Factor 3 Tumor Suppressor Activity in B16 Melanoma Tumors¹

Terry Fox Molecular Oncology Group, Lady Davis Institute-Jewish General Hospital [D. D., F. M., J. S., M. S., R. L., J. G., J. H.], and Departments of Microbiology and Immunology [D. D., J. H.], and Medicine [F. J., J. S., M. S., R. L., J. G., J. H.], McGill University, Montreal, Quebec H3T-1E2; School of Veterinary Medicine, Université de Montreal [D. M.], Montreal, Quebec H3C 3J7; and Center for Cell and Gene Therapy, Department of Pathology, McMaster University, Hamilton, Ontario L8N 3Z5 [J. B.], Canada

Delivery of transcription factors to cancer cells to reprogram gene expressionmay represent a novel strategy to augment the production of immunestimulatory cytokines and trigger a more potent antitumor response. In the present study, a bicistronic retroviral vector (AP2) was used to transduce B16-F0 melanoma cells with IFN regulatory factor (IRF)-3, which has been shown to activate type I IFN genes (IFN-ß and IFN-) as well as other cytokines. Gene-modified B16 melanoma cells were inoculated s.c. into C57BL/6 syngeneic mice. In animals receiving IRF-3 B16 melanoma cells, tumors grew at a 4- to 5-fold reduced rate, and tumors that developed from these mice had a moderate-to-dense infiltration of inflammatory cells, whereas only low levels of lymphocyte infiltration were observed in mock-transduced B16 tumors. Furthermore, tumor growth was not inhibited in severe-combined immunodeficient mice after inoculation of IRF-3-expressing B16 cells, which suggested that IRF-3-mediated antitumor responses were dependent on a functional adaptive lymphocyte response. Interestingly, these in vivo effects on tumor growth correlated with higher mRNA expression of chemokines such as MIP-1ß, RANTES, and IP-10, as well as dramatic increases in vitro in the inducibility of cytokine mRNA such as IFN-ß, TNF- and interleukin 6. Our results demonstrate that with weakly antigenic tumors such as B16 melanoma, IRF-3 gene transfer can mediate important antitumor responses. These findings suggest a novel role for IRF-3 as a potential molecular target for gene therapy of cancer.

This article has been cited by other articles:

				J.-T. Wang, S.-L. Doong, S.-C. Teng, C.-P. Lee, C.-H. Tsai, and M.-R. Chen Epstein-Barr Virus BGLF4 Kinase Suppresses the Interferon Regulatory Factor 3 Signaling Pathway J. Virol., February 15, 2009; 83(4): 1856 - 1869. [Abstract] [Full Text] [PDF]

				C. M. Bailey, D. E. Abbott, N. V. Margaryan, Z. Khalkhali-Ellis, and M. J. C. Hendrix Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner Mol. Cell. Biol., April 1, 2008; 28(7): 2235 - 2243. [Abstract] [Full Text] [PDF]

				A. A. Lugade, E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, and E. M. Lord Radiation-Induced IFN-{gamma} Production within the Tumor Microenvironment Influences Antitumor Immunity J. Immunol., March 1, 2008; 180(5): 3132 - 3139. [Abstract] [Full Text] [PDF]

				T.-K. Kim, J.-S. Lee, S.-Y. Oh, X. Jin, Y.-J. Choi, T.-H. Lee, E. h. Lee, Y.-K. Choi, S. You, Y. G. Chung, et al. Direct Transcriptional Activation of Promyelocytic Leukemia Protein by IFN Regulatory Factor 3 Induces the p53-Dependent Growth Inhibition of Cancer Cells Cancer Res., December 1, 2007; 67(23): 11133 - 11140. [Abstract] [Full Text] [PDF]

				Z. J. Roberts, N. Goutagny, P.-Y. Perera, H. Kato, H. Kumar, T. Kawai, S. Akira, R. Savan, D. van Echo, K. A. Fitzgerald, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis J. Exp. Med., July 9, 2007; 204(7): 1559 - 1569. [Abstract] [Full Text] [PDF]

				R. Romieu-Mourez, M. Solis, A. Nardin, D. Goubau, V. Baron-Bodo, R. Lin, B. Massie, M. Salcedo, and J. Hiscott Distinct Roles for IFN Regulatory Factor (IRF)-3 and IRF-7 in the Activation of Antitumor Properties of Human Macrophages Cancer Res., November 1, 2006; 66(21): 10576 - 10585. [Abstract] [Full Text] [PDF]

				S. Goriely, C. Molle, M. Nguyen, V. Albarani, N. O. Haddou, R. Lin, D. De Wit, V. Flamand, F. Willems, and M. Goldman Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation Blood, February 1, 2006; 107(3): 1078 - 1084. [Abstract] [Full Text] [PDF]

				C. M. Bailey, Z. Khalkhali-Ellis, S. Kondo, N. V. Margaryan, R. E. B. Seftor, W. W. Wheaton, S. Amir, M. R. Pins, B. C. Schutte, and M. J. C. Hendrix Mammary Serine Protease Inhibitor (Maspin) Binds Directly to Interferon Regulatory Factor 6: IDENTIFICATION OF A NOVEL SERPIN PARTNERSHIP J. Biol. Chem., October 7, 2005; 280(40): 34210 - 34217. [Abstract] [Full Text] [PDF]

				T. Y. Kim, K.-H. Lee, S. Chang, C. Chung, H.-W. Lee, J. Yim, and T. K. Kim Oncogenic Potential of a Dominant Negative Mutant of Interferon Regulatory Factor 3 J. Biol. Chem., April 18, 2003; 278(17): 15272 - 15278. [Abstract] [Full Text] [PDF]